Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

International Groups Express Concern About Cambodian 'AIDS Colony'
In an open letter to Cambodia"s prime minister and health minister, more than 100 international HIV/AIDS advocates and human rights organizations "accused the Cambodian government of herding HIV-affected families into an "AIDS colony" outside the capital, Phnom Penh," the Guardian reports (McCurry, 7/28).
generic viagra online
CMA Commends Dept. Of Insurance Regulations That Will Protect Patients From Losing Their Health Insurance, California
The California Medical Association today praised the state Department of Insurance (DOI) for conducting a public hearing this week on its proposed regulations to prevent private insurers from unjustly canceling health coverage for patients after they get sick and file an expensive claim. The DOI released the proposed regulations last month.
News of the day
Redefining How A Chronic Auto-Immune Disease Is Diagnosed
New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is diagnosed. Eduardo De Sousa, M.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and director of the Electrodiagnostic Neuromuscular Lab at JHN, led the study which looked at the number of demyelinating features that are needed to differentiate between CIDP, Amyotrophic lateral sclerosis (ALS, or Lou Gehrig"s disease) and diabetic neuropathy. His research suggests a minimum number of three demyelinating features can be used to positively identify CIDP in a patient. CIDP is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. It affects about 50,000 people in the United States. The study, available in the current edition of the Journal of Clinical Neuromuscular Disease, may help doctors more effectively diagnose and treat CIDP.
Endocrinology

FDA Reviewing Preliminary Safety Information On Asthma Drug Xolair

The U.S. Food and Drug Administration announced that it is conducting a safety review of Xolair (omalizumab), a drug used to treat certain adults and adolescents with moderate-to-severe persistent asthma. Reviewers are looking for a possible association between patients who use Xolair and an increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke. The possible association has been identified based on interim results from an ongoing study of Xolair known as Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS). The study is being conducted by the manufacturer, San Francisco-based Genentech Inc. An FDA Early Communication is available online. The Early Communication is in keeping with the FDA"s commitment to inform the public about its ongoing safety reviews of drugs. Once its review is completed, the FDA will communicate its findings and any resulting recommendations to the public. Until the evaluation is completed, health care professionals and patients should be aware that the agency is reviewing data that may suggest a risk of adverse events. The FDA is not advising a change in prescribing or use of the drug. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009